Boiron laboratories confirm their recovery – Le Journal des Entreprises

After several tumultuous years following the delisting of homeopathy in France, the Boiron group has returned to growth in 2022. Its turnover is indeed up slightly (+17.4%). It climbed 9.4% in France, despite the decline in sales of non-proprietary homeopathic medicines which continues, thanks to the increase in sales of homeopathic specialties and other health products. Internationally, Boiron recorded +26.1%. Sales of Covid tests are down.